Reply
Jessica Musto, Michael R. Lucey, John Rice – 9 December 2021
Jessica Musto, Michael R. Lucey, John Rice – 9 December 2021
Bing Han, Maria Giovanna Francipane, Amin Cheikhi, Joycelyn Johnson, Fei Chen, Ruoyu Chen, Eric Lagasse – 9 December 2021
Hannah S.J. Choi, Alexander Tonthat, Harry L.A. Janssen, Norah A. Terrault – 9 December 2021 – Chronic hepatitis B virus (HBV) infection remains difficult to cure due to the persistent, self‐replenishing nature of the viral genome and impaired host immune responses. Current treatment goals for chronic hepatitis B (CHB) are to prevent or significantly delay liver‐related adverse outcomes and death, and two types of treatments are available: nucleos(t)ide analogues (NAs) and interferons (IFNs).
Jovan Julien, Turgay Ayer, Elliot B. Tapper, Carolina Barbosa, William N. Dowd, Jagpreet Chhatwal – 7 December 2021
Marta Librero Jiménez, María Ángeles López Garrido, María Carmen Fernández Cano – 7 December 2021
Hillary J. Braun, Nancy L. Ascher – 6 December 2021
Ravi Jariwala, Mohamed Shoreibah – 6 December 2021
Hillary J. Braun, Nancy L. Ascher – 6 December 2021
Ravi Jariwala, Mohamed Shoreibah – 6 December 2021